No Result

View All Result

No products in the cart.

2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑

Home StudyGraphics

#VisualAbstract: Seladelpar for the treatment of primary biliary cholangitis

byMinjee Kim

February 23, 2024

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract: Seladelpar for the treatment of primary biliary cholangitis

Click here to read this study in NEJM.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Carvedilol linked to lower cirrhosis complication risk

Seladelpar (Livdelzi) raises the bar for primary biliary cholangitis treatment

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

Presence of unmet social needs associated with lower utilization of breast cancer screening programs

RelatedReports

Increasing survival rates for patients with acute liver failure

Gastroenterology

Carvedilol linked to lower cirrhosis complication risk

July 6, 2026

Increased risk of stillbirth recurrence after a previous stillbirth

All Specialties

Seladelpar (Livdelzi) raises the bar for primary biliary cholangitis treatment

June 9, 2026

Pharma

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

June 3, 2026

Low evidence for glycerin use in preterm infants

Pediatrics

Neonatal Hyperbilirubinemia and navigating the 2022 AAP guideline updates

February 6, 2026

Early physical activity post-injury may result in lower post-concussive symptom burden in children

Epileptogenic foci may be lateralized using functional brain glutamate imaging

Penetrating traumatic brain injuries associated with greater risk of brain cancer amongst veterans

Thrombophilia-associated stillbirth risk appears limited to factor V Leiden

History of infertility may be associated with worse cardiovascular health at mid-life

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract: Seladelpar for the treatment of primary biliary cholangitis

Carvedilol linked to lower cirrhosis complication risk

Seladelpar (Livdelzi) raises the bar for primary biliary cholangitis treatment

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

Presence of unmet social needs associated with lower utilization of breast cancer screening programs

Early physical activity post-injury may result in lower post-concussive symptom burden in children

RelatedReports

Carvedilol linked to lower cirrhosis complication risk

Seladelpar (Livdelzi) raises the bar for primary biliary cholangitis treatment

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

Neonatal Hyperbilirubinemia and navigating the 2022 AAP guideline updates

Early physical activity post-injury may result in lower post-concussive symptom burden in children

Penetrating traumatic brain injuries associated with greater risk of brain cancer amongst veterans

History of infertility may be associated with worse cardiovascular health at mid-life

2MM+ All Access

Recent Reports

The medical literature, distilled daily.

Membership benefits